Abstract
Extensive research over the past two decades in tumor immunology has shown that immune reactivity to tumor antigens can restrict tumor growth and/or metastasis, especially when tumor burden is low. These observations in experimental models have been translated into clinical studies involving both active and passive forms of immunotherapies. While immune responses to specific tumor antigens can be detected in patients with various types of cancers, responses to any single antigen seldom correlate directly with a clinical response to tumors; however, some clinical regressions of solid tumors have been reported with certain types of cancer vaccines. While passive immunotherapies with antibody to tumor antigens (Avastin®, Herceptin®, Erbitux®, RituxanTM, BexxarTM) are being used to treat selected types of cancers, active immunotherapies may be better suited to potentially elicit a sustained immune response, particularly when administered in an adjuvant setting. This review covers the potential and issues with specific active immunotherapies (SAI) for the treatment of cancer.
Keywords: Tumor antigens, Active immunotherapy, Cancer vaccines, Clinical trials
Reviews on Recent Clinical Trials
Title: Specific Active Immunotherapy of Cancer: Potential and Perspectives
Volume: 1 Issue: 3
Author(s): Roopa Srinivasan and Dennis E. Van Epps
Affiliation:
Keywords: Tumor antigens, Active immunotherapy, Cancer vaccines, Clinical trials
Abstract: Extensive research over the past two decades in tumor immunology has shown that immune reactivity to tumor antigens can restrict tumor growth and/or metastasis, especially when tumor burden is low. These observations in experimental models have been translated into clinical studies involving both active and passive forms of immunotherapies. While immune responses to specific tumor antigens can be detected in patients with various types of cancers, responses to any single antigen seldom correlate directly with a clinical response to tumors; however, some clinical regressions of solid tumors have been reported with certain types of cancer vaccines. While passive immunotherapies with antibody to tumor antigens (Avastin®, Herceptin®, Erbitux®, RituxanTM, BexxarTM) are being used to treat selected types of cancers, active immunotherapies may be better suited to potentially elicit a sustained immune response, particularly when administered in an adjuvant setting. This review covers the potential and issues with specific active immunotherapies (SAI) for the treatment of cancer.
Export Options
About this article
Cite this article as:
Srinivasan Roopa and Van Epps E. Dennis, Specific Active Immunotherapy of Cancer: Potential and Perspectives, Reviews on Recent Clinical Trials 2006; 1 (3) . https://dx.doi.org/10.2174/157488706778250113
DOI https://dx.doi.org/10.2174/157488706778250113 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitory Effects of Novel SphK2 Inhibitors on Migration of Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Management of Vulvar Cancer
Reviews on Recent Clinical Trials Involvement of IL-1R/TLR Signalling in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Molecular Medicine Universal Human Papillomavirus Vaccination and its Impact on the Southern Italian Region
Current Pharmaceutical Design Applications and Toxicity of Silver Nanoparticles: A Recent Review
Current Topics in Medicinal Chemistry Patent Analysis as a Tool for Research Planning: Study on Natural Based Therapeutics Against Cancer Stem Cells
Recent Patents on Anti-Cancer Drug Discovery Dysregulation of Neurotrophic and Haematopoietic Growth Factors in Alzheimer’s Disease: From Pathophysiology to Novel Treatment Strategies
Current Alzheimer Research An Overview of HDAC Inhibitors and their Synthetic Routes
Current Topics in Medicinal Chemistry Implications of Photophysical and Physicochemical Factors on Successful Application of Photodynamic Therapy
Current Pharmaceutical Design Muscular Dystrophies: Histology, Immunohistochemistry, Molecular Genetics and Management
Current Pharmaceutical Design Peptide Nucleic Acids with a Structurally Biased Backbone: Effects of Conformational Constraints and Stereochemistry
Current Topics in Medicinal Chemistry MicroRNAs in Breast Cancer: One More Turn in Regulation
Current Drug Targets Near-Infrared Quantum Dot Contrast Agents for Fluorescence Tissue Imaging: A Phantom Study
Current Nanoscience 1'-methylspiro[indoline-3,4'-piperidine] Derivatives: Design, Synthesis, Molecular Docking and Anti-tumor Activity Studies
Letters in Drug Design & Discovery The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design Synthesis and Antiproliferative Evaluation of Hybrids of Indolin-2-one and Quinazoline-4(3H)-one Linked via Imine Bond
Letters in Drug Design & Discovery Activities of Venom Proteins and Peptides with Possible Therapeutic Applications from Bees and WASPS
Protein & Peptide Letters Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Antimicrobial and Anti-Inflammatory Activities of a Leu/Lys-Rich Antimicrobial Peptide with Phe-Peptoid Residues
Protein & Peptide Letters Promotion of Cortico-Cerebral Precursors Expansion by Artificial pri-miRNAs Targeted Against the Emx2 Locus
Current Gene Therapy